Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05961111 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05928962 | An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas | unknown | Phase 1 | 10 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05451407 | Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma | unknown | Phase 1 | 50 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03803397 | Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03989895 | Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03990493 | Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT05827289 | 'Cancer Patients Better Life Experience'(CAPABLE) | unknown | N/A | 36 | The Netherlands Cancer InstituteOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05223218 | Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study | unknown | — | 500 | Namida LabINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05478473 | Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma | unknown | N/A | 43 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05889481 | Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma(MicroGenUM) | unknown | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05906277 | Biobanking and New Biomolecular Metrics(Melamoma4p) | unknown | N/A | 300 | Regina Elena Cancer InstituteOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05106023 | To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma | unknown | Phase 2 | 31 | Yong ChenOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05263453 | HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation | unknown | Phase 2 | 104 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05823246 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 2 | 66 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT05854589 | Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number. | unknown | Phase 2 | 20 | Rafik BatroussyOTHER | 0 | May 11, 2023 | clinicaltrials |
| NCT03683550 | Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma | unknown | N/A | 836 | University Hospital, EssenOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05723432 | KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma | unknown | Phase 1 / Phase 2 | 84 | Shanghai Kanda Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05827770 | The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma | unknown | Phase 2 | 20 | Yong ChenOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03313544 | Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 | unknown | Phase 4 | 50 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | unknown | Phase 2 | 52 | Suthee RapisuwonOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT03743298 | Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma | unknown | Phase 1 | 20 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT04821570 | To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment(CANINE) | unknown | — | 500 | University of Kansas Medical CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05156515 | PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor | unknown | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03132675 | Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment(Keynote-695) | unknown | Phase 2 | 143 | OncoSec Medical IncorporatedINDUSTRY | 5 | Mar 27, 2023 | clinicaltrials |
| NCT05783882 | Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma(FLAT) | unknown | Phase 3 | 114 | BiocadINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05767879 | (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | unknown | Phase 2 | 28 | Leiden University Medical CenterOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05750511 | Multicenter Tissue Registry in Melanoma(TRIM) | unknown | — | 1,000 | Dermatologic Cooperative Oncology GroupOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05744076 | Analysis of Circulating Exosomes in Melanoma Patients(EXOMEL1) | unknown | — | 150 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03534635 | Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) | unknown | Phase 2 | 30 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04747561 | Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant Melanoma | unknown | N/A | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05645484 | The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma | unknown | — | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04107168 | Microbiome Immunotherapy Toxicity and Response Evaluation | unknown | — | 1,800 | CCTU- Cancer ThemeOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05664139 | Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Feb 8, 2023 | clinicaltrials |
| NCT03166397 | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | unknown | Phase 2 | 30 | Sheba Medical CenterOTHER_GOV | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05145829 | Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients(SCARLETT) | unknown | N/A | 40 | Zuyderland Medisch CentrumOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04436406 | PD-L1 Expression in Cancer (PECan Study).(PECan) | unknown | N/A | 30 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05641012 | Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma(Helioma) | unknown | — | 100 | Institut Jean-GodinotOTHER | 0 | Dec 7, 2022 | clinicaltrials |
| NCT04633902 | Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | unknown | Phase 2 | 41 | California Pacific Medical Center Research InstituteOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05077280 | A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma | unknown | Phase 2 | 40 | California Pacific Medical Center Research InstituteOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05051865 | To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma | unknown | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05406466 | Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT02036086 | Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | unknown | Phase 2 | 24 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT01955915 | Blood Vessel Patterns in Small Choroidal Tumors | unknown | — | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569707 | MR Lymphography and Magnetic Sentinel Lymph Node Biopsy in Melanoma Patients(MelaDiff) | unknown | N/A | 20 | University of TwenteOTHER | 1 | Oct 6, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2023source: clinicaltrials